Certain Warrants of Sera Prognostics, Inc. are subject to a Lock-Up Agreement Ending on 10-JAN-2022.
January 09, 2022
Share
Certain Warrants of Sera Prognostics, Inc. are subject to a Lock-Up Agreement Ending on 10-JAN-2022. These Warrants will be under lockup for 180 days starting from 14-JUL-2021 to 10-JAN-2022.
Details:
The officers and directors and substantially all of stockholders of equity securities have entered into a lock up agreement pursuant to which, they will not to offer, sell, contract to sell, pledge or otherwise dispose of, including the filing of a registration statement in respect of, or hedge any shares of Class A common stock or any securities convertible into or exchangeable or exercisable for common stock, for a period of 180 days from the date of the final prospectus, without the prior written consent of Citigroup Global Markets Inc., Cowen and Company, LLC and William Blair & Company, L.L.C., on behalf of the underwriters.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant motherâs risk of delivering spontaneously before 37 weeksâ gestation.
SERA PROGNOSTICS, INC. 
